Venetoclax Alone and in Combination with Bendamustine/Rituximab for Relapsed/Refractory NHL 


Venetoclax Alone and in Combination with Bendamustine/Rituximab for Relapsed/Refractory NHL 
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Jeff Sharman, MD (2/9/16)

Gerecitano JF et al. A Phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Proc ASH 2015;Abstract 254.

de Vos S et al. A dose-escalation study of venetoclax (ABT-199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma. Proc ASH 2015;Abstract 255.

Dr Sharman is Director of Research at the Willamette Valley Cancer Institute and Medical Director of Hematology Research at The US Oncology Network in Eugene, Oregon.